SCHEMBL5779687

SCHEMBL5779687

CCOc1c(C(=O)O)n(C)c2cc(CNc3nccn3C(c3ccccc3)(c3ccccc3)c3ccccc3)ccc2c1=O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
ACSS2 Q9NR19 2/20 0.33
ALDH1A1 P00352 7/20 0.32
KDM4E B2RXH2 4/20 0.32
TSHR P16473 2/20 0.32
GAA P10253 2/20 0.32
ALOX15 P16050 1/20 0.32
HPGD P15428 6/20 0.32
CYP1A2 P05177 3/20 0.32
CYP2C9 P11712 3/20 0.32
PPARG P37231 1/20 0.32
MAPT P10636 4/20 0.32
THRB P10828 2/20 0.32
LMNA P02545 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
KMT2A Q03164 1/20 0.32
KLKB1 P03952 1/20 0.31
HTT P42858 1/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8635242 0.95 NPC1 (0.31) NPC1RAB9AACSS2ALDH1A1KDM4E
SCHEMBL27608112 0.83 KMT2A (0.35) ALDH1A1KDM4ETSHRGAAALOX15
SCHEMBL4388255 0.80 S1PR1 (0.40) NPC1RAB9ATHRBLMNAPOLB
SCHEMBL12372084 0.80 P2RX3 (0.42) RAB9AALDH1A1KDM4ETSHRHPGD
SCHEMBL5779683 0.78 S1PR1 (0.36) NPC1RAB9AALDH1A1THRBLMNA
SCHEMBL4654929 0.73 CAMK2D (0.37)
SCHEMBL7055717 0.72 S1PR1 (0.41) NPC1RAB9AALDH1A1MAPTLMNA
SCHEMBL4654781 0.72 P2RX3 (0.40) ALDH1A1TSHRMAPT
SCHEMBL5663451 0.71 CNR1 (0.35) HPGDLMNAPOLB
SCHEMBL7052174 0.71 P2RX3 (0.39) ALDH1A1TSHRMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0944619-B1 NOVEL INTEGRIN RECEPTOR ANTAGONISTS BRISTOL MYERS SQUIBB PHARMA CO (US) 2006-10-11 EP disclosed
US-6358976-B1 FOR THERAPY AND PROPHYLAXIS OF CANCER METASTASIS, DIABETIC RETINOPATHY, NEOVASCULAR GLAUCOMA, THROMBOSIS, RESTENOSIS, OSTEOPOROSIS, OR MACULAR DEGENERATION LANTHEUS MI REAL ESTATE, LLC 2002-03-19 US disclosed
US-6130231-A SUBSTITUTED 2,3-DIHYDROQUINOLIN-4-ONES DUPONT PHARMACEUTICALS (US) 2000-10-10 US disclosed